Vaccine strategy SIgA anti-FIV-p241 SIgA anti-HIV gp1202 Week 2 Week 4 Week 6 Week 8 Week 8 IM 1:300 Negative Negative Negative 1:19,200 IM Not Tested 1:2,400 Negative 1:300 1:1,2003 IM+ A(1-7) Not Tested 1:300 Negative 1:300 1:1,2003 Topical gel only 1:300 Negative Negative Negative Negative3 0.1 mg A(1-7) 1:300 1:19,200 1:300 1:300 1:9,600 0.2 mg A(1-7) 1:300 1:4,800 Negative Negative 1:2,400 0.3 mg A(1-7) 1:300 1:300 Negative Negative 1:19,200 0.4 mg A(1-7) 1:1,200 1:300 1:300 1:1,200 1:9,600 5.0 mg A(1-7) 1:1,200 Negative Negative Negative 1:1,2003 7.5 mg A(1-7) Negative Negative 1:2,400 Negative 1:38,4003 10.0 mg A(1-7) Negative Negative Negative Negative 1:2,4003

1Undiluted was the lowest dilution tested with an elution factor of 300-fold. 21:4 was the lowest dilution tested with an elution factor of 300-fold. 3Sample tested was from week 6. 4Secretory IgG antibodies were not tested at this mucosal site due to insufficient sample.

Table 4: Rectal secretory antibody titers.